Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria

This study developed and explored a novel composite endpoint to assess the overall impact that treatment can have on patients living with paroxysmal nocturnal hemoglobinuria (PNH). Candidate composite endpoint variables were selected by a group of experts and included: lactate dehydrogenase levels a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulasekararaj, Austin, Glasmacher, Axel, Liu, Peng, Szer, Jeff, Araten, David, Rauch, Geraldine, Gwaltney, Chad, Sierra, J Rafael, Lee, Jong Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311164/
https://www.ncbi.nlm.nih.gov/pubmed/35100459
http://dx.doi.org/10.1111/ejh.13746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311164/
https://www.ncbi.nlm.nih.gov/pubmed/35100459
http://dx.doi.org/10.1111/ejh.13746

Ejemplares similares